NASDAQ:VIRI

Virios Therapeutics (VIRI) Stock Forecast, Price & News

$1.72

+0.06 (+3.61%)

(As of 05/31/2023 ET)

Compare

Today's Range: $1.61
▼
$1.81
50-Day Range: $0.31
▼
$1.72
52-Week Range: $0.22
▼
$9.11

Volume: 836,262 shs
Average Volume: 1.96 million shs
Market Capitalization: $14.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Virios Therapeutics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
3.93% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.96
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.28) to ($0.29) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.52 out of 5 stars

Medical Sector

925th out of 1,006 stocks

Pharmaceutical Preparations Industry

462nd out of 492 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Virios Therapeutics.

5.0

Short Interest

Percentage of Shares Shorted
3.93% of the outstanding shares of Virios Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Virios Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Virios Therapeutics has recently decreased by 68.81%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Virios Therapeutics does not currently pay a dividend.
Dividend Growth
Virios Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VIRI.

3.3

News and Social Media Coverage

News Sentiment
Virios Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Virios Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 9 people have searched for VIRI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
6 people have added Virios Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Virios Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.90% of the stock of Virios Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.63% of the stock of Virios Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Virios Therapeutics are expected to decrease in the coming year, from ($0.28) to ($0.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Virios Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Virios Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Virios Therapeutics has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Virios Therapeutics (NASDAQ:VIRI) Stock

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Receive VIRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VIRI Stock News Headlines

May 25, 2023 | finance.yahoo.com

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 16, 2023 | finance.yahoo.com

VIRI: Ready to Move IMC-1 Into Phase 3 Program…

June 1, 2023 | UNKNOWN (Ad)

This NASDAQ Stock Is The Amazon Of Medical Supply

This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now

May 16, 2023 | americanbankingnews.com

Virios Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:VIRI)

May 15, 2023 | finance.yahoo.com

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

May 12, 2023 | marketwatch.com

10-Q: VIRIOS THERAPEUTICS, INC.

May 12, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Virios Therapeutics (VIRI)

May 11, 2023 | benzinga.com

Recap: Virios Therapeutics Q1 Earnings

June 1, 2023 | UNKNOWN (Ad)

This NASDAQ Stock Is The Amazon Of Medical Supply

This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now

May 11, 2023 | finance.yahoo.com

Virios Therapeutics Announces First Quarter 2023 Financial Results

May 11, 2023 | americanbankingnews.com

Virios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest Update

May 10, 2023 | msn.com

Earnings Preview: Virios Therapeutics

May 9, 2023 | americanbankingnews.com

Virios Therapeutics (VIRI) Set to Announce Earnings on Thursday

May 4, 2023 | finance.yahoo.com

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

April 25, 2023 | proactiveinvestors.com

Virios Therapeutics stock doubles as fibromyalgia program moves forward

April 25, 2023 | marketwatch.com

Virios Therapeutics Shares Rise 52% After FDA Feedback for IMC-1

April 25, 2023 | msn.com

Why Virios Therapeutics (VIRI) Stock Is Skyrocketing

April 25, 2023 | finance.yahoo.com

Virios Therapeutics Shares Almost Double In Trading Session - Here's Why

April 25, 2023 | investorplace.com

Why Is Virios Therapeutics (VIRI) Stock Up 92% Today?

April 24, 2023 | finance.yahoo.com

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

March 30, 2023 | americanbankingnews.com

Short Interest in Virios Therapeutics, Inc. (NASDAQ:VIRI) Increases By 52.5%

March 27, 2023 | msn.com

Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session

March 18, 2023 | benzinga.com

Watching Virios Therapeutics; Zacks Small-Cap Research Sets $2 Valuation

March 16, 2023 | finance.yahoo.com

VIRI: Anticipating Update on IMC-1 Following ‘End-of-Phase 2’ Meeting with FDA…

March 14, 2023 | finance.yahoo.com

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

March 14, 2023 | finance.yahoo.com

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

March 7, 2023 | finance.yahoo.com

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VIRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VIRI Company Calendar

Last Earnings: 3/14/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VIRI
CUSIP: N/A
CIK: 1818844
Web: www.virios.com
Phone: 866-620-8655
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,250,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -132.21%
Return on Assets: -112.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.88
Quick Ratio: 11.88

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.72 per share
Price / Book: 2.39

Miscellaneous

Outstanding Shares: 8,330,000
Free Float: 6,672,000
Market Cap: $14.33 million
Optionable: Not Optionable
Beta: 2.05

Key Executives

Mr. Gregory Duncan (Age 57)
Chairman & CEO
Comp: $798.67k

Mr. Ralph D. Grosswald M.P.H. (Age 53)
Sr. VP of Operations
Comp: $274.69k

Dr. R. Michael Gendreau M.D. (Age 66)
Ph.D., Chief Medical Officer
Comp: $459.9k

Ms. Angela Walsh (Age 55)
CFO, SVP of Fin., Corp. Sec. & Treasurer

Ms. Carol Duffy Ph.D.
Chief Scientific Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VIRI Stock - Frequently Asked Questions

Should I buy or sell Virios Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Virios Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VIRI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIRI, but not buy additional shares or sell existing shares.
View VIRI analyst ratings or view top-rated stocks.
How have VIRI shares performed in 2023?: Virios Therapeutics' stock was trading at $0.2360 at the beginning of 2023. Since then, VIRI shares have increased by 628.8% and is now trading at $1.72.
View the best growth stocks for 2023 here.
Are investors shorting Virios Therapeutics?: Virios Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 327,500 shares, a decrease of 68.8% from the April 30th total of 1,050,000 shares. Based on an average daily volume of 2,790,000 shares, the days-to-cover ratio is presently 0.1 days.
View Virios Therapeutics' Short Interest.
When is Virios Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our VIRI earnings forecast.
How were Virios Therapeutics' earnings last quarter?: Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its quarterly earnings data on Tuesday, March, 14th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05.
When did Virios Therapeutics IPO?: (VIRI) raised $30 million in an IPO on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is Virios Therapeutics' stock symbol?: Virios Therapeutics trades on the NASDAQ under the ticker symbol "VIRI."
Who are Virios Therapeutics' major shareholders?: Virios Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (1.94%) and Envestnet Asset Management Inc. (1.45%). Insiders that own company stock include Angela Walsh, Gregory Scott Duncan, Richard James Whitley and William Pridgen.
View institutional ownership trends.
How do I buy shares of Virios Therapeutics?: Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Virios Therapeutics' stock price today?: One share of VIRI stock can currently be purchased for approximately $1.72.
How much money does Virios Therapeutics make?: Virios Therapeutics (NASDAQ:VIRI) has a market capitalization of $14.33 million. The company earns $-12,250,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.
How can I contact Virios Therapeutics?: The official website for the company is www.virios.com. The company can be reached via phone at 866-620-8655 or via email at ir@virios.com.

This page (NASDAQ:VIRI) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial